MEDI5752 in Combination with Carboplatin plus Pemetrexed in Unresectable Pleural Mesothelioma - eVOLVE-Meso

Study identifier:D7988C00001

ClinicalTrials.gov identifier:NCT06097728

EudraCT identifier:2023-000067-32

CTIS identifier:2023-503231-17-00

Recruiting

Official Title

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Medical condition

Unresectable Pleural mesothelioma

Phase

Phase 3

Healthy volunteers

No

Study drug

Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, Ipilimumab

Sex

All

Estimated Enrollment

600

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 09 Nov 2023
Estimated Primary Completion Date: 15 Mar 2027
Estimated Study Completion Date: 13 Mar 2028

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria